Lantheus Holdings, Inc. (LNTH)
NASDAQ: LNTH · Real-Time Price · USD
100.46
+0.14 (0.14%)
At close: Oct 30, 2026, 4:00 PM EDT
100.46
0.00 (0.00%)
After-hours: Oct 30, 2026, 7:30 PM EDT
Lantheus Holdings Employees
Lantheus Holdings had 1,193 employees as of December 31, 2025. The number of employees increased by 385 or 47.65% compared to the previous year. That makes Lantheus Holdings the 13,661st largest employer in the world and 2,078th in the United States.
Employees
1,193
Change (1Y)
385
Growth (1Y)
47.65%
Revenue / Employee
$1,304,537
Profits / Employee
$230,767
Market Cap
6.56B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 1,193 | 385 | 47.65% |
| Dec 31, 2024 | 808 | -26 | -3.12% |
| Dec 31, 2023 | 834 | 136 | 19.48% |
| Dec 31, 2022 | 698 | 86 | 14.05% |
| Dec 31, 2021 | 612 | 17 | 2.86% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Dr. Reddy's Laboratories | 27,527 |
| Elanco Animal Health | 9,900 |
| Amneal Pharmaceuticals | 8,700 |
| Neurocrine Biosciences | 2,500 |
| Hims & Hers Health | 2,442 |
| Alkermes | 2,050 |
| Indivior Pharmaceuticals | 838 |
| Kiniksa Pharmaceuticals International, | 366 |
LNTH News
- 17 days ago - Lantheus downgraded to Neutral from Outperform at Mizuho - TheFly
- 17 days ago - Lantheus downgraded to Neutral from Outperform at Mizuho - TheFly
- 24 days ago - BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Option Care Health, Inc. (Nasdaq – OPCH), Lantheus Holdings Inc. (Nasdaq – LNTH), MarketAxess Holdings Inc. (Nasdaq – MKTX), Sangoma Technologies Corporation (Nasdaq – SANG) - GlobeNewsWire
- 4 weeks ago - Lantheus Holdings Proxy statement: Proxy filing - Filings
- 4 weeks ago - Lantheus announces CMS granted TPT payment status for PYLARIFY TruVu injection - TheFly
- 4 weeks ago - Lantheus Announces CMS Grants Transitional Pass-Through Status for PYLARIFY® TruVu (piflufolastat F 18) - GlobeNewsWire
- 4 weeks ago - BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: SoundThinking, Inc. (Nasdaq – SSTI), Lantheus Holdings Inc. (Nasdaq – LNTH), MarketAxess Holdings Inc. (Nasdaq – MKTX), Sangoma Technologies Corporation (Nasdaq – SANG) - GlobeNewsWire
- 4 weeks ago - Lantheus announces first patient dosed in Phase 2/3 trial of LNTH-2401 - TheFly